학술논문

First efficacy assessment of a phase II study with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone plus rituximab, administered every two weeks (R-COMP-14) as primary treatment for NHL
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; JUN 20 2007, 25 18, 2p. Supplement: S
Subject
Language
English
ISSN
15277755